北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 内分泌科  > 期刊论文
学科主题: 临床医学
题名:
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
作者: Ji, L.1; Han, P.2; Liu, Y.3; Yang, G.4; Van, N. K. Dieu5; Vijapurkar, U.6; Qiu, R.6; Meininger, G.6
关键词: phase III study ; sodium glucose co-transporter 2 (SGLT2) inhibitor ; type 2 diabetes
刊名: DIABETES OBESITY & METABOLISM
发表日期: 2015
DOI: 10.1111/dom.12385
卷: 17, 期:1, 页:23-31
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Endocrinology & Metabolism
研究领域[WOS]: Endocrinology & Metabolism
关键词[WOS]: PLACEBO-CONTROLLED TRIAL ; DOUBLE-BLIND ; RANDOMIZED-TRIAL ; PLUS SULFONYLUREA ; ADD-ON ; EFFICACY ; SAFETY ; MONOTHERAPY ; MELLITUS ; SITAGLIPTIN
英文摘要:

Aims: To evaluate the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin or metformin in combination with sulphonylurea.

Methods: In this 18-week, randomized, double-blind, placebo-controlled phase III study, patients (N = 676) received canagliflozin 100 or 300 mg or placebo once daily. The primary efficacy endpoint was change in glycated haemoglobin (HbA1c) level from baseline at week 18. Additional endpoints included change in fasting plasma glucose (FPG) and percent change in body weight. Adverse events (AEs) were recorded throughout the study. Efficacy and safety were assessed in the overall population and in two strata based on background therapy.

Results: At week 18, canagliflozin 100 and 300 mg provided significant reductions from baseline in HbA1c compared with placebo (-0.97, -1.06 and -0.47%, respectively; p<0.001). Relative to placebo, canagliflozin 100 and 300 mg also significantly reduced FPG (-1.0 and -1.4 mmol/l) and body weight [-2.2% (-1.5 kg) and -2.3% (-1.6 kg)]. Both canagliflozin doses lowered systolic blood pressure (BP) compared with placebo. The overall incidence of AEs was 38.6, 43.2 and 42.0% with canagliflozin 100 and 300 mg and placebo, respectively. The incidence of genital mycotic infections and urinary tract infections was low and similar across groups. Efficacy and safety findings in the two strata were generally consistent with the overall population.

Conclusions: Canagliflozin provided glycaemic improvements and reductions in body weight and systolic BP, and was generally well tolerated in Asian patients with T2DM on metformin or metformin in combination with sulphonylurea.

语种: 英语
项目资助者: Janssen Research &amp ; Development, LLC. ; Janssen Global Services, LLC.
WOS记录号: WOS:000348848300005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50575
Appears in Collections:北京大学第二临床医学院_内分泌科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Jilin Univ, Hosp 2, Changchun 130023, Peoples R China
2.Peking Univ, Ctr Diabet, Peoples Hosp, Beijing 100871, Peoples R China
3.China Med Univ, Shengjing Hosp, Shenyang 110001, Peoples R China
4.Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China
5.Bach Mai Hosp, Dept Endocrinol, Hanoi, Vietnam
6.Janssen Res & Dev LLC, Raritan, NJ USA

Recommended Citation:
Ji, L.,Han, P.,Liu, Y.,et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea[J]. DIABETES OBESITY &amp; METABOLISM,2015,17(1):23-31.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Ji, L.]'s Articles
[Han, P.]'s Articles
[Liu, Y.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Ji, L.]‘s Articles
[Han, P.]‘s Articles
[Liu, Y.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace